Verato Enrich is powered by the company's cloud-based enterprise master person index. It can append a wide array of data ranging from basic contact information like missing phone numbers and addresses, to lifestyle data like income, ethnicity, race, occupation, and interests to patient records.
Approximately 80% of positive COVID-19 test results are submitted electronically and current reports show that as many as 50% lack enough contact data to support contact tracing.
With Verato Enrich, health systems, commercial labs, and public health teams gain an increased understanding of people and the critical non-clinical factors that impact health.
Enrich acts as an accelerator, enabling contact tracing and analysis to be more efficient and effective. Shortening the cycle between infection notification and actionable data is the only way to ensure a rapid response and contain the virus.
Verato Enrich extends the value proposition of Verato's next-generation EMPI, providing a critical infrastructure backbone for contact tracing and public health analytics, enabling health organisations to accurately integrate information from a range of sources and efficiently drive actionable workflows and information sharing.
Verato is the next generation of EMPI and patient matching.
As a HITRUST-certified EMPI, over 50 of the nation's most innovative healthcare organizations rely on Verato Referential Matching to manage and link person data quickly and at scale.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return